1019018-13-3

Basic information

• Product Name: 4-Amino-3-chloro-N,N-dimethylbenzamide
• Synonyms: 4-Amino-3-chloro-N,N-dimethylbenzamide
• CAS NO: 1019018-13-3
• Molecular Weight: 198.652
• Mol File: 1019018-13-3.mol

Chemical Properties

• CAS DataBase Reference: 4-Amino-3-chloro-N,N-dimethylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-3-chloro-N,N-dimethylbenzamide(1019018-13-3)
• EPA Substance Registry System: 4-Amino-3-chloro-N,N-dimethylbenzamide(1019018-13-3)

Safety Data

• Hazardous Substances Data: 1019018-13-3(Hazardous Substances Data)

Upstream product

• 16761-18-5 4-acetamido-3-chlorobenzenesulphonyl chloride 
• 124-40-3 dimethyl amine 
• 2486-71-7 4-amino-3-chlorobenzoic acid 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 1189816-47-4 8-bromo-N-(2-chloro-4-(dimethylcarbamoyl)phenyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 1400285-89-3 3-chloro-N,N-dimethyl-4-(2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-ylamino)benzamide 
• 1400284-70-9 tert-butyl 6-((2-chloro-4-(dimethylcarbamoyl)phenyl)amino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-26-8 tert-butyl 3-chloro-6-(2-chloro-4-(dimethylcarbamoyl)phenylamino)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-59-7 tert-butyl-6-(2-chloro-4-(dimethylcarbamoyl)phenylamino)-2-(oxazol-5-yl)-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 1400285-25-7 3-chloro-4-(1-(cyclopentylmethyl)-2-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridin-6-ylamino)-N,N-dimethylbenzamide 
• 1189816-49-6 2-((2-chloro-4-(dimethylcarbamoyl)phenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-8-carboxylic acid 
• 1189816-48-5 methyl 2-((2-chloro-4-(dimethylcarbamoyl)phenyl)(methyl)carbamoyl)-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-8-carboxylate 
• 1189816-46-3 8-bromo-N-(2-chloro-4-(dimethylcarbamoyl)phenyl)-N-methyl-4,5-dihydrobenzo[b]thieno[2,3-d]oxepine-2-carboxamide 
• 1189812-14-3 GNE-614 

Relevant articles and documents

INHIBITOR COMPOUNDS

The present invention relates to compounds of formula (I), wherein R, R, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 - also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them

Structure-based design of orally bioavailable 1 h -Pyrrolo[3,2- C ]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)

The protein kinase MPS1 is a crucial component of the spindle assembly checkpoint signal and is aberrantly overexpressed in many human cancers. MPS1 is one of the top 25 genes overexpressed in tumors with chromosomal instability and aneuploidy. PTEN-defic

Rational design of phosphoinositide 3-kinase inhibitors that exhibit selectivity over the phosphoinositide 3-kinase isoform

Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3K has justly received the most attention for its potential in cancer therapy. Herein we report our successful approaches to achieve PI3K vs PI3K selectivity for two chemical series. In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3K that is not attained with the corresponding Lys777 of PI3K. In the benzoxepin series of inhibitors, the selectivity observed can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.

NOVEL PYRROLOY2,3-d¨PYRIMIDINE COMPOUND

Disclosed is a novel pyrrolo[2,3-d]pyrimidine compound represented by formula [I] or a pharmacologically acceptable salt thereof, which has a GPR119 receptor agonistic activity and is useful for a pharmaceutical. In formula [I], E represents a group repre

BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.